Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-11-12 (Wednesday)	84,466	USD 38,241,137	USD 38,241,137	216	USD 164,349	USD 452.74	USD 451.95
2025-11-11 (Tuesday)	84,250	USD 38,076,788	USD 38,076,788	0	USD 863,563	USD 451.95	USD 441.7
2025-11-10 (Monday)	84,250	USD 37,213,225	USD 37,213,225	215	USD 10,930	USD 441.7	USD 442.7
2025-11-07 (Friday)	84,035	USD 37,202,295	USD 37,202,295	0	USD 185,718	USD 442.7	USD 440.49
2025-11-06 (Thursday)	84,035	USD 37,016,577	USD 37,016,577	215	USD 591,758	USD 440.49	USD 434.56
2025-11-05 (Wednesday)	83,820	USD 36,424,819	USD 36,424,819	0	USD 929,564	USD 434.56	USD 423.47
2025-11-04 (Tuesday)	83,820	USD 35,495,255	USD 35,495,255	216	USD -794,733	USD 423.47	USD 434.07
2025-11-03 (Monday)	83,604	USD 36,289,988	USD 36,289,988	0	USD -1,836,780	USD 434.07	USD 456.04
2025-10-31 (Friday)	83,604	USD 38,126,768	USD 38,126,768	0	USD 541,754	USD 456.04	USD 449.56
2025-10-30 (Thursday)	83,604	USD 37,585,014	USD 37,585,014	1,080	USD -2,157,719	USD 449.56	USD 481.59
2025-10-29 (Wednesday)	82,524	USD 39,742,733	USD 39,742,733	621	USD 764,276	USD 481.59	USD 475.91
2025-10-28 (Tuesday)	81,903	USD 38,978,457	USD 38,978,457	0	USD -218,681	USD 475.91	USD 478.58
2025-10-27 (Monday)	81,903	USD 39,197,138	USD 39,197,138	0	USD 1,240,831	USD 478.58	USD 463.43

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BDZVHG35

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 BUY 216 459.270 447.130 448.344 USD 96,842 305.86
2025-11-10 BUY 215 449.680 440.930 441.805 USD 94,988 304.38
2025-11-06 BUY 215 445.490 429.000 430.649 USD 92,590 302.93
2025-11-04 BUY 216 431.500 421.830 422.797 USD 91,324 301.58
2025-10-30 BUY 1,080 471.980 436.512 440.059 USD 475,263 299.22
2025-10-29 BUY 621 481.590 482.730 482.616 USD 299,704 298.22
2025-10-22 SELL -864 464.900 480.530 478.967 USD -413,827 293.41 Loss of -160,319 on sale
2025-10-20 BUY 432 491.220 495.550 495.117 USD 213,891 291.26
2025-10-17 BUY 1,079 481.670 492.620 491.525 USD 530,355 290.18
2025-10-15 BUY 1,720 470.270 485.280 483.779 USD 832,100 289.14
2025-10-03 BUY 1,498 456.350 465.010 464.144 USD 695,288 287.12
2025-10-02 BUY 214 460.990 461.530 461.476 USD 98,756 286.10
2025-09-30 BUY 428 456.000 459.300 458.970 USD 196,439 284.07
2025-09-26 BUY 428 446.400 453.050 452.385 USD 193,621 282.11
2025-09-25 BUY 428 449.580 459.000 458.058 USD 196,049 281.11
2025-09-18 BUY 196 452.170 456.940 456.463 USD 89,467 280.07
2025-09-17 BUY 588 451.730 463.880 462.665 USD 272,047 279.02
2025-09-11 SELL -196 468.580 474.340 473.764 USD -92,858 274.39 Loss of -39,077 on sale
2025-09-10 BUY 392 469.310 480.050 478.976 USD 187,759 273.17
2025-07-17 SELL -392 324.690 329.870 329.352 USD -129,106 270.87 Loss of -22,923 on sale
2025-07-16 BUY 680 322.810 323.410 323.350 USD 219,878 270.54
2025-07-11 SELL -1,552 314.940 321.120 320.502 USD -497,419 269.68 Loss of -78,883 on sale
2025-07-02 BUY 10,670 329.770 330.000 329.977 USD 3,520,855 268.13
2025-06-25 BUY 388 321.940 324.320 324.082 USD 125,744 266.62
2025-06-20 SELL -6,084 309.700 314.500 314.020 USD -1,910,498 265.56 Loss of -294,810 on sale
2025-06-13 BUY 121 307.990 308.020 308.017 USD 37,270 263.92
2025-06-11 BUY 430 298.580 303.850 303.323 USD 130,429 263.35
2025-06-10 BUY 430 302.460 308.890 308.247 USD 132,546 263.05
2025-06-04 SELL -215 305.310 308.930 308.568 USD -66,342 261.76 Loss of -10,064 on sale
2025-04-23 BUY 215 241.970 248.590 247.928 USD 53,305 257.63
2025-04-10 SELL -1,720 226.280 235.330 234.425 USD -403,211 260.05 Profit of 44,068 on sale
2025-04-08 SELL -215 224.320 246.150 243.967 USD -52,453 260.65 Profit of 3,587 on sale
2025-04-07 SELL -215 232.950 241.830 240.942 USD -51,803 260.97 Profit of 4,306 on sale
2025-04-04 SELL -1,075 235.740 259.160 256.818 USD -276,079 261.27 Profit of 4,784 on sale
2025-04-01 BUY 1,845 255.760 273.610 271.825 USD 501,517 261.27
2025-03-31 SELL -633 270.020 271.850 271.667 USD -171,965 261.16 Loss of -6,650 on sale
2025-03-21 BUY 2,889 283.340 289.440 288.830 USD 834,430 259.89
2025-03-14 SELL -3,232 241.760 244.040 243.812 USD -788,000 260.64 Profit of 54,385 on sale
2025-03-07 SELL -404 244.520 251.120 250.460 USD -101,186 262.20 Profit of 4,741 on sale
2025-03-04 SELL -202 242.930 244.670 244.496 USD -49,388 262.93 Profit of 3,724 on sale
2025-02-25 BUY 404 245.200 251.560 250.924 USD 101,373 264.62
2025-02-19 SELL -202 250.510 254.010 253.660 USD -51,239 265.69 Profit of 2,429 on sale
2025-02-13 BUY 606 264.890 268.520 268.157 USD 162,503 266.39
2025-02-12 BUY 202 265.960 268.200 267.976 USD 54,131 266.39
2025-02-11 BUY 808 268.990 273.230 272.806 USD 220,427 266.34
2025-01-02 BUY 102 233.620 239.990 239.353 USD 24,414 263.76
2024-12-30 SELL -6,947 236.010 236.950 236.856 USD -1,645,439 264.60 Profit of 192,714 on sale
2024-11-18 SELL -3,300 232.270 242.490 241.468 USD -796,844 280.15 Profit of 127,640 on sale
2024-11-08 SELL -220 277.430 279.510 279.302 USD -61,446 281.14 Profit of 405 on sale
2024-10-30 BUY 117 281.490 287.870 287.232 USD 33,606 290.50
2024-10-21 SELL -220 292.010 295.390 295.052 USD -64,911 0.00 Loss of -64,911 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	BUY	216	459.270	447.130	448.344	USD 96,842	305.86
2025-11-10	BUY	215	449.680	440.930	441.805	USD 94,988	304.38
2025-11-06	BUY	215	445.490	429.000	430.649	USD 92,590	302.93
2025-11-04	BUY	216	431.500	421.830	422.797	USD 91,324	301.58
2025-10-30	BUY	1,080	471.980	436.512	440.059	USD 475,263	299.22
2025-10-29	BUY	621	481.590	482.730	482.616	USD 299,704	298.22
2025-10-22	SELL	-864	464.900	480.530	478.967	USD -413,827	293.41 Loss of -160,319 on sale
2025-10-20	BUY	432	491.220	495.550	495.117	USD 213,891	291.26
2025-10-17	BUY	1,079	481.670	492.620	491.525	USD 530,355	290.18
2025-10-15	BUY	1,720	470.270	485.280	483.779	USD 832,100	289.14
2025-10-03	BUY	1,498	456.350	465.010	464.144	USD 695,288	287.12
2025-10-02	BUY	214	460.990	461.530	461.476	USD 98,756	286.10
2025-09-30	BUY	428	456.000	459.300	458.970	USD 196,439	284.07
2025-09-26	BUY	428	446.400	453.050	452.385	USD 193,621	282.11
2025-09-25	BUY	428	449.580	459.000	458.058	USD 196,049	281.11
2025-09-18	BUY	196	452.170	456.940	456.463	USD 89,467	280.07
2025-09-17	BUY	588	451.730	463.880	462.665	USD 272,047	279.02
2025-09-11	SELL	-196	468.580	474.340	473.764	USD -92,858	274.39 Loss of -39,077 on sale
2025-09-10	BUY	392	469.310	480.050	478.976	USD 187,759	273.17
2025-07-17	SELL	-392	324.690	329.870	329.352	USD -129,106	270.87 Loss of -22,923 on sale
2025-07-16	BUY	680	322.810	323.410	323.350	USD 219,878	270.54
2025-07-11	SELL	-1,552	314.940	321.120	320.502	USD -497,419	269.68 Loss of -78,883 on sale
2025-07-02	BUY	10,670	329.770	330.000	329.977	USD 3,520,855	268.13
2025-06-25	BUY	388	321.940	324.320	324.082	USD 125,744	266.62
2025-06-20	SELL	-6,084	309.700	314.500	314.020	USD -1,910,498	265.56 Loss of -294,810 on sale
2025-06-13	BUY	121	307.990	308.020	308.017	USD 37,270	263.92
2025-06-11	BUY	430	298.580	303.850	303.323	USD 130,429	263.35
2025-06-10	BUY	430	302.460	308.890	308.247	USD 132,546	263.05
2025-06-04	SELL	-215	305.310	308.930	308.568	USD -66,342	261.76 Loss of -10,064 on sale
2025-04-23	BUY	215	241.970	248.590	247.928	USD 53,305	257.63
2025-04-10	SELL	-1,720	226.280	235.330	234.425	USD -403,211	260.05 Profit of 44,068 on sale
2025-04-08	SELL	-215	224.320	246.150	243.967	USD -52,453	260.65 Profit of 3,587 on sale
2025-04-07	SELL	-215	232.950	241.830	240.942	USD -51,803	260.97 Profit of 4,306 on sale
2025-04-04	SELL	-1,075	235.740	259.160	256.818	USD -276,079	261.27 Profit of 4,784 on sale
2025-04-01	BUY	1,845	255.760	273.610	271.825	USD 501,517	261.27
2025-03-31	SELL	-633	270.020	271.850	271.667	USD -171,965	261.16 Loss of -6,650 on sale
2025-03-21	BUY	2,889	283.340	289.440	288.830	USD 834,430	259.89
2025-03-14	SELL	-3,232	241.760	244.040	243.812	USD -788,000	260.64 Profit of 54,385 on sale
2025-03-07	SELL	-404	244.520	251.120	250.460	USD -101,186	262.20 Profit of 4,741 on sale
2025-03-04	SELL	-202	242.930	244.670	244.496	USD -49,388	262.93 Profit of 3,724 on sale
2025-02-25	BUY	404	245.200	251.560	250.924	USD 101,373	264.62
2025-02-19	SELL	-202	250.510	254.010	253.660	USD -51,239	265.69 Profit of 2,429 on sale
2025-02-13	BUY	606	264.890	268.520	268.157	USD 162,503	266.39
2025-02-12	BUY	202	265.960	268.200	267.976	USD 54,131	266.39
2025-02-11	BUY	808	268.990	273.230	272.806	USD 220,427	266.34
2025-01-02	BUY	102	233.620	239.990	239.353	USD 24,414	263.76
2024-12-30	SELL	-6,947	236.010	236.950	236.856	USD -1,645,439	264.60 Profit of 192,714 on sale
2024-11-18	SELL	-3,300	232.270	242.490	241.468	USD -796,844	280.15 Profit of 127,640 on sale
2024-11-08	SELL	-220	277.430	279.510	279.302	USD -61,446	281.14 Profit of 405 on sale
2024-10-30	BUY	117	281.490	287.870	287.232	USD 33,606	290.50
2024-10-21	SELL	-220	292.010	295.390	295.052	USD -64,911	0.00 Loss of -64,911 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE